-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Insmed, Lowers Price Target to $195

Benzinga·06/05/2026 14:03:04
Listen to the news
RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $205 to $195.